| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Daniel G. Stover | Q47155703 |
| Ewy Mathé | Q52374858 | ||
| P2093 | author name string | James L Chen | |
| John L Hays | |||
| P2860 | cites work | DNA Sequencing versus Standard Prenatal Aneuploidy Screening | Q22250872 |
| HMDB: the Human Metabolome Database | Q23039065 | ||
| Improved exome prioritization of disease genes through cross-species phenotype comparison | Q23815226 | ||
| DECIPHER: database for the interpretation of phenotype-linked plausibly pathogenic sequence and copy-number variation | Q24567711 | ||
| HMDB 3.0--The Human Metabolome Database in 2013 | Q24595162 | ||
| Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease | Q24601951 | ||
| Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk | Q24603491 | ||
| HMDB: a knowledgebase for the human metabolome | Q24655295 | ||
| Metabolomics Workbench: An international repository for metabolomics data and metadata, metabolite standards, protocols, tutorials and training, and analysis tools | Q24698644 | ||
| Integration with the human genome of peptide sequences obtained by high-throughput mass spectrometry | Q24805791 | ||
| Impact of the gut microbiota on inflammation, obesity, and metabolic disease | Q26751430 | ||
| Integration of omics: more than the sum of its parts | Q26768503 | ||
| Data standards can boost metabolomics research, and if there is a will, there is a way | Q26776402 | ||
| Blue Button use by patients to access and share health record information using the Department of Veterans Affairs' online patient portal | Q26782239 | ||
| Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine | Q26783472 | ||
| Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity | Q26992272 | ||
| The human gut microbiome and body metabolism: implications for obesity and diabetes | Q26995303 | ||
| The Chemical Translation Service--a web-based tool to improve standardization of metabolomic reports | Q27062596 | ||
| Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. | Q27853162 | ||
| Deep learning | Q28018765 | ||
| Glypican-1 identifies cancer exosomes and detects early pancreatic cancer | Q36781050 | ||
| Metabolomics: an emerging but powerful tool for precision medicine | Q36851433 | ||
| Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures | Q36881534 | ||
| Bayes and empirical Bayes methods for reduced rank regression models in matched case-control studies | Q36909483 | ||
| Urinary Metabolite Risk Biomarkers of Lung Cancer: A Prospective Cohort Study | Q36963678 | ||
| Interplay between Metabolism and Epigenetics: A Nuclear Adaptation to Environmental Changes | Q36969070 | ||
| Predicting time to ovarian carcinoma recurrence using protein markers. | Q37123908 | ||
| Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy | Q37193459 | ||
| Host-Microbiome Interaction and Cancer: Potential Application in Precision Medicine | Q28069401 | ||
| Circulating mutant DNA to assess tumor dynamics | Q28289337 | ||
| Age-related clonal hematopoiesis associated with adverse outcomes | Q28386602 | ||
| Two elephants in the room: new hybrid nuclear magnetic resonance and mass spectrometry approaches for metabolomics | Q28611329 | ||
| Assays for investigating deSUMOylation enzymes | Q28678204 | ||
| The MetaboLights repository: curation challenges in metabolomics | Q28707581 | ||
| The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013 | Q28710185 | ||
| Data sharing in the post-genomic world: the experience of the International Cancer Genome Consortium (ICGC) Data Access Compliance Office (DACO) | Q28727215 | ||
| Advances in structure elucidation of small molecules using mass spectrometry | Q28743720 | ||
| Metabolomics enables precision medicine: "A White Paper, Community Perspective" | Q28831476 | ||
| Analysis of circulating tumor DNA to monitor metastatic breast cancer | Q29614797 | ||
| Proteomics. Tissue-based map of the human proteome | Q29617248 | ||
| Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA | Q29620083 | ||
| Ontology-based data integration between clinical and research systems | Q30000636 | ||
| Advances in understanding cancer genomes through second-generation sequencing | Q30014827 | ||
| Mixing omics: combining genetics and metabolomics to study rheumatic diseases | Q30238656 | ||
| Sharing Data to Build a Medical Information Commons: From Bermuda to the Global Alliance | Q30401131 | ||
| An efficient diagnosis system for Parkinson's disease using kernel-based extreme learning machine with subtractive clustering features weighting approach. | Q30423403 | ||
| Similarity network fusion for aggregating data types on a genomic scale | Q30742291 | ||
| Interactive XCMS Online: simplifying advanced metabolomic data processing and subsequent statistical analyses | Q30831518 | ||
| Methods of integrating data to uncover genotype-phenotype interactions | Q30884207 | ||
| Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis | Q31127142 | ||
| Metabox: A Toolbox for Metabolomic Data Analysis, Interpretation and Integrative Exploration | Q31158395 | ||
| Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses | Q33415400 | ||
| An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. | Q33590850 | ||
| Finding the right questions: exploratory pathway analysis to enhance biological discovery in large datasets | Q33687179 | ||
| Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm | Q33880795 | ||
| Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. | Q33909660 | ||
| Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood | Q33965667 | ||
| Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin | Q34123261 | ||
| Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis | Q34125617 | ||
| PASSEL: the PeptideAtlas SRMexperiment library | Q34154235 | ||
| Cell metabolomics | Q37199564 | ||
| Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy | Q37200505 | ||
| Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. | Q37206520 | ||
| Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer | Q37240839 | ||
| Existing and emerging technologies for tumor genomic profiling | Q37255147 | ||
| MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. | Q37410615 | ||
| Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer | Q37438981 | ||
| Review of mass spectrometry-based metabolomics in cancer research | Q37550758 | ||
| The state of the human proteome in 2012 as viewed through PeptideAtlas | Q37591292 | ||
| High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial | Q37682595 | ||
| Proteogenomic integration reveals therapeutic targets in breast cancer xenografts | Q37736390 | ||
| Advances in metabolite identification | Q37914159 | ||
| Modern analytical techniques in metabolomics analysis | Q37958864 | ||
| Lessons from the cancer genome | Q38094259 | ||
| Computational tools for the secondary analysis of metabolomics experiments | Q38201036 | ||
| A rough guide to metabolite identification using high resolution liquid chromatography mass spectrometry in metabolomic profiling in metazoans | Q38201037 | ||
| Emerging field of metabolomics: big promise for cancer biomarker identification and drug discovery. | Q38311249 | ||
| Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. | Q38379925 | ||
| GeneYenta: a phenotype-based rare disease case matching tool based on online dating algorithms for the acceleration of exome interpretation | Q38415903 | ||
| Exploring the emerging complexity in transcriptional regulation of energy homeostasis | Q38605684 | ||
| Genomic Evolution of Breast Cancer Metastasis and Relapse | Q38623761 | ||
| Microbiome and metabolome data integration provides insight into health and disease | Q38648247 | ||
| AACR Project GENIE: Powering Precision Medicine through an International Consortium | Q38749978 | ||
| Emerging applications of metabolomics in drug discovery and precision medicine | Q38769103 | ||
| Metabolite and Microbiome Interplay in Cancer Immunotherapy | Q38800832 | ||
| Monitoring cancer prognosis, diagnosis and treatment efficacy using metabolomics and lipidomics. | Q38822368 | ||
| A targeted metabolomics assay for cardiac metabolism and demonstration using a mouse model of dilated cardiomyopathy | Q38830822 | ||
| Profiling cancer metabolism at the 'omic' level: a last resort or the next frontier? | Q39252856 | ||
| Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. | Q39636313 | ||
| A guide to the identification of metabolites in NMR-based metabonomics/metabolomics experiments. | Q39884399 | ||
| Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety | Q39933788 | ||
| APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism | Q40063761 | ||
| Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells | Q40220260 | ||
| Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer | Q40364937 | ||
| Multiplexed Elimination of Wild-Type DNA and High-Resolution Melting Prior to Targeted Resequencing of Liquid Biopsies | Q40483796 | ||
| SMART on FHIR Genomics: facilitating standardized clinico-genomic apps | Q40711214 | ||
| Navigating freely-available software tools for metabolomics analysis | Q41332699 | ||
| Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer | Q41354811 | ||
| Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. | Q41431886 | ||
| Clinical utility of circulating cell-free DNA in advanced colorectal cancer | Q41545171 | ||
| Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer | Q41605016 | ||
| The emergence of genome-based drug repositioning | Q42080559 | ||
| Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. | Q42183079 | ||
| Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. | Q43045850 | ||
| Challenges in circulating tumour cell research | Q43500645 | ||
| Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer | Q44670943 | ||
| Error-correction learning for artificial neural networks using the Bayesian paradigm. Application to automated medical diagnosis. | Q44999164 | ||
| Direct detection of early-stage cancers using circulating tumor DNA. | Q46035548 | ||
| Metabolomics: beyond biomarkers and towards mechanisms | Q46206242 | ||
| LinkedOmics: analyzing multi-omics data within and across 32 cancer types | Q47106278 | ||
| Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. | Q47214510 | ||
| Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas. | Q47577223 | ||
| Maximal clique method for the automated analysis of NMR TOCSY spectra of complex mixtures | Q47820330 | ||
| Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer | Q47905634 | ||
| Detection and localization of surgically resectable cancers with a multi-analyte blood test. | Q48216212 | ||
| Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. | Q48655131 | ||
| Tracking tumor resistance using 'liquid biopsies'. | Q48721300 | ||
| NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial. | Q48842485 | ||
| Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients. | Q49079173 | ||
| Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer. | Q49342704 | ||
| Extracellular vesicles compartment in liquid biopsies: Clinical application. | Q49862013 | ||
| Evaluation of a Methotrexate Chemiluminescent Microparticle Immunoassay: Comparison to Fluorescence Polarization Immunoassay and Liquid Chromatography-Tandem Mass Spectrometry. | Q51274763 | ||
| Experimental and Study Design Considerations for Uncovering Oncometabolites. | Q51347860 | ||
| IntLIM: integration using linear models of metabolomics and gene expression data. | Q52366931 | ||
| Mass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibitors in triple negative breast cancers. | Q52374520 | ||
| RaMP: A Comprehensive Relational Database of Metabolomics Pathways for Pathway Enrichment Analysis of Genes and Metabolites. | Q52374814 | ||
| CancerLinQ Update. | Q54385071 | ||
| Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology. | Q55261883 | ||
| Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia | Q60305981 | ||
| Untargeted metabolomics | Q84015844 | ||
| Flagging flora: heart disease link | Q84911363 | ||
| NCI-MATCH pairs tumor mutations with matching drugs | Q85852392 | ||
| The strengths and weaknesses of NMR spectroscopy and mass spectrometry with particular focus on metabolomics research | Q86717444 | ||
| Personalized Medicine-Disregarding the Obvious: Analysis of Trends Among Articles Published on "Personalized Medicine" | Q86911936 | ||
| Detecting cancer by monitoring circulating tumor DNA | Q87827554 | ||
| Early Intervention in Lung Cancers With Rapid Plasma Genotyping for EGFR and KRAS Mutations | Q87842409 | ||
| Opportunities for Patient Matching Algorithms to Improve Patient Care in Oncology | Q91108392 | ||
| Isolation and characterization of DNA from the plasma of cancer patients | Q34186554 | ||
| XCMS Online: a web-based platform to process untargeted metabolomic data | Q34245491 | ||
| Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. | Q34278191 | ||
| Effect of a clinical trial alert system on physician participation in trial recruitment | Q34293754 | ||
| Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer | Q34500359 | ||
| Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer | Q34533164 | ||
| Molecular profiling of single circulating tumor cells with diagnostic intention | Q34542660 | ||
| Neoplastic characteristics of the DNA found in the plasma of cancer patients | Q34543792 | ||
| The NCI Genomic Data Commons as an engine for precision medicine | Q34682174 | ||
| The dynamic range of circulating tumor DNA in metastatic breast cancer | Q35000808 | ||
| Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma | Q35042544 | ||
| Analytical methods in untargeted metabolomics: state of the art in 2015. | Q35149924 | ||
| Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism | Q35159836 | ||
| Increasing the efficiency of trial-patient matching: automated clinical trial eligibility pre-screening for pediatric oncology patients | Q35532193 | ||
| MetaboAnalyst 3.0--making metabolomics more meaningful | Q35610559 | ||
| Predicting postoperative complications of head and neck squamous cell carcinoma in elderly patients using random forest algorithm model | Q35656992 | ||
| Metabolomics for Biomarker Discovery: Moving to the Clinic | Q35674401 | ||
| Using fragmentation trees and mass spectral trees for identifying unknown compounds in metabolomics | Q35715135 | ||
| Cancer biomarker discovery and validation | Q35879887 | ||
| Targeted metabolomics | Q35906724 | ||
| Variant Calling From Next Generation Sequence Data | Q35967686 | ||
| Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations | Q35970350 | ||
| Proteogenomics connects somatic mutations to signalling in breast cancer | Q36037203 | ||
| Diet-microbiota interactions as moderators of human metabolism | Q36069065 | ||
| Measuring the metabolome: current analytical technologies | Q36106252 | ||
| Natural products as mediators of disease. | Q36200942 | ||
| A review on mass spectrometry-based quantitative proteomics: Targeted and data independent acquisition. | Q36326056 | ||
| Matching cancer genomes to established cell lines for personalized oncology | Q36336519 | ||
| Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood | Q36497457 | ||
| Application of imaging mass spectrometry for the molecular diagnosis of human breast tumors. | Q36574461 | ||
| Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients | Q36586155 | ||
| Integrated metabolomics and metagenomics analysis of plasma and urine identified microbial metabolites associated with coronary heart disease | Q36638223 | ||
| An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma | Q36732789 | ||
| The biology and function of exosomes in cancer | Q36737945 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P433 | issue | 1 | |
| P921 | main subject | proteomics | Q471857 |
| medical oncology | Q6050805 | ||
| cell-free nucleic acid | Q66981054 | ||
| P304 | page(s) | 211-222 | |
| P577 | publication date | 2018-08-01 | |
| 2018-08-29 | |||
| P1433 | published in | Yearbook of medical informatics : Advances in an interdisciplinary science | Q26842317 |
| P1476 | title | The Omics Revolution Continues: The Maturation of High-Throughput Biological Data Sources | |
| P478 | volume | 27 |
| Q98230839 | A Network-Based "Phenomics" Approach for Discovering Patient Subtypes From High-Throughput Cardiac Imaging Data |
| Q64988161 | Artificial Intelligence and Personalized Medicine. |
| Q57173841 | Cancer Informatics in 2017: A New Beginning and a Bright Future |
| Q91816891 | Comparison of commercially available whole-genome sequencing kits for variant detection in circulating cell-free DNA |
| Q98467279 | Multiomics profiling of paired primary and recurrent glioblastoma patient tissues |
| Q92725121 | Proteomic investigations into hypertension: what's new and how might it affect clinical practice? |
Search more.